TruthArchive.ai - Related Video Feed

Video Saved From X

reSee.it Video Transcript AI Summary
I found something interesting for Elon and the Doge team regarding Medicare. In 2022, Medicare filled 85,000 prescriptions for Perfinidone at $8,000 each, totaling $680 million. At my cost-plus pharmacy, the same prescription is only $200. Filling all 85,000 prescriptions with me would only cost $17 million. Medicare is overpaying by $663 million annually because Pharmacy Benefits Managers (PBMs) get a percentage of the cost, incentivizing them to inflate prices. The easy solution is to cancel the PBM contracts and use actual costs. If you want to check if PBMs have been raising the cost of your medications, go to forestparkpharmacy.com and check our price to see how much you could save.

Video Saved From X

reSee.it Video Transcript AI Summary
The speaker's administration will implement "most favored nations" drug pricing, ensuring Americans pay the lowest price for drugs compared to other developed countries. Some prescription drug prices will be reduced almost immediately by 50% to 90%. Big Pharma must voluntarily comply or the federal government will ensure equal pricing. To accelerate price reductions, the administration will cut out the middlemen to facilitate direct drug sales to American citizens at the most favored nation price. The speaker believes the middlemen are worse than drug companies because they don't make a product but make a fortune.

Video Saved From X

reSee.it Video Transcript AI Summary
One breast cancer drug costs over $16,000 per bottle in America. The same drug, from the same factory and company, costs one sixth the price in Australia. In Sweden, the identical product costs one tenth the American price.

Video Saved From X

reSee.it Video Transcript AI Summary
The speaker claims the United States spends $1,126 per capita on drugs, while Britain spends about $240, approximately one-fifth of the U.S. figure, a trend seen across Europe. The speaker says drug companies claim America must pay for pharmaceutical innovation. President Trump is quoted as saying European partners need to increase their drug payments to cover their share of innovation, asserting the U.S. should no longer subsidize it. The speaker concludes that if Europeans raised drug prices by 20%, the resulting $10 trillion could be spent on innovation, improving global health.

Video Saved From X

reSee.it Video Transcript AI Summary
Brenzavvy, a drug similar to Jardiance or Farxiga, is not covered by insurance, prescribed by doctors, or carried by wholesalers because it is too cheap. Brenzavvy costs $60 at the speaker's pharmacy. Pharmacy benefits managers (PBMs) deny coverage because Brenzavvy's low price prevents rebates. Farxiga and Jardiance cost insurance payers $1,000 upfront with a 40% rebate. An HHS report stated PBMs get 23% on average for brand meds. After rebates, Farxiga and Jardiance still cost $600, with PBMs earning $138. With 8,000,000 prescriptions a year, PBMs make $1,100,000,000 off those two drugs. The speaker claims PBMs keep Brenzavvy off their lists to avoid losing a billion dollars annually. The speaker believes affordable healthcare is impossible with PBMs involved. The speaker encourages listeners to use forestpark.pharmacy to save money and to inform their bosses about potential savings.

Video Saved From X

reSee.it Video Transcript AI Summary
Former President Trump claims that he was the only president to take on big pharma, but Joe Biden canceled his toughened pharmaceutical policies. Trump signed an executive order to ensure that the US government pays the same price for pharmaceuticals as other countries, saving American patients billions of dollars. However, Biden reversed this order, allowing other countries to negotiate lower prices while Americans pay high prices. Trump promises that if he is reelected, he will sign an executive order to end this unfair practice and make Big Pharma lower prices for American patients. He believes that rescinding his original order shows the power of Big Pharma, but he is determined to deliver savings for seniors and all American patients.

Video Saved From X

reSee.it Video Transcript AI Summary
I am implementing a rebate that cuts out the middlemen in the drug industry, reducing costs and benefiting the people purchasing the drugs. Despite facing opposition from wealthy individuals, I believe this is our only opportunity to make a change. No other president would take the steps I am taking, such as implementing favored nations and buying from other countries at lower prices. These actions have made a lot of rich people unhappy, but I am determined to prioritize the well-being of the people over their profits.

Video Saved From X

reSee.it Video Transcript AI Summary
The U.S. spends $1,126 per capita on drugs, while Britain spends about $240, roughly one-fifth of the U.S. amount, a trend seen across Europe. Drug companies claim America must pay for innovation. President Trump argues that European partners need to increase their drug payments to cover their share of innovation, asserting the U.S. will no longer subsidize them. If Europeans raise drug prices by 20%, $10 trillion could be spent on innovation, improving global health through better products.

Video Saved From X

reSee.it Video Transcript AI Summary
I am implementing a rebate that cuts out the middlemen in the drug industry, reducing costs and benefiting the people who purchase the drugs. This has made me a target for wealthy individuals who are not pleased with my actions. However, I believe that we have a unique opportunity to make a change that no other president would dare to do. By implementing a favored nations approach and buying drugs from other countries at lower prices, we can further reduce costs. Despite the opposition from these rich individuals, I am determined to continue with this initiative.

Video Saved From X

reSee.it Video Transcript AI Summary
I aim to eliminate middlemen and reduce costs in the pharmaceutical industry, allowing the money saved to benefit drug purchasers. Unlike drug companies, who produce tangible products, these middlemen do not contribute in the same way. My enemies, who are wealthy individuals, are displeased with my actions. However, I believe this is our only opportunity to make a change, as no other president would take such steps. This may be my last appearance for a while.

Video Saved From X

reSee.it Video Transcript AI Summary
Politicians have long promised to eliminate the discrepancy between drug prices in the U.S. and Europe. This was a key issue for Bernie Sanders, but previous leaders haven't acted on it. Politicians make these promises knowing they likely won't have to fulfill them. The reason is that Congress is heavily influenced by the pharmaceutical industry. There is at least one pharmaceutical lobbyist for every congressman, senator, and Supreme Court member.

Video Saved From X

reSee.it Video Transcript AI Summary
Robert F. Kennedy Jr. praises President Trump for addressing the discrepancy between US and European drug prices, a promise unfulfilled by previous Democratic leaders due to pharmaceutical industry influence. Kennedy claims there is at least one pharmaceutical lobbyist for every congressman, senator, and Supreme Court member, and the industry spends three times more on lobbying than any other. Kennedy states that Trump cannot be bought and is standing up to oligarchs, unlike other politicians. He notes that the US, with 4.2% of the world's population, accounts for 75% of pharmaceutical company revenues, spending $11.26 per capita on drugs compared to Britain's $240. Kennedy says Trump is asking European partners to increase their drug payments to fund innovation, suggesting a 20% increase would free up $10 trillion for innovation and improve global health.

Video Saved From X

reSee.it Video Transcript AI Summary
We're paying too much for drugs compared to other countries, and existing laws make it hard to lower costs. The middlemen in the drug industry are profiting significantly without adding value. We're going to eliminate these middlemen to reduce drug prices to unprecedented levels. This topic dominated our discussions with executives and others involved.

Video Saved From X

reSee.it Video Transcript AI Summary
Medicare overspent on dimethyl fumarate in 2022, paying $590 million for a drug I offer at $65 per prescription. This discrepancy highlights how Pharmacy Benefits Managers (PBMs) inflate drug costs to increase their profits. Medicare's PBM charged them $3,800 per prescription when the real price is only $65. This PBM price gouging cost Medicare $580 million on just this one drug. The solution is simple: eliminate PBM contracts to save money. Also, your insurance likely uses a PBM, overcharging you too. Check if you're overpaying for your medications at fourthparkpharmacy.com to use our price checker.

Video Saved From X

reSee.it Video Transcript AI Summary
One breast cancer drug costs Americans over $16,000 per bottle. The same drug, from the same factory, manufactured by the same company, costs one-sixth the price in Australia. In Sweden, the identical product costs one-tenth the price.

Video Saved From X

reSee.it Video Transcript AI Summary
We are working to ensure fair pricing for drugs developed with taxpayer money. If drug companies set high prices that Americans can't afford, the government can allow other companies to produce and sell the same drug at a lower cost. This promotes competition, lowers costs, raises wages, and improves care. We are also cracking down on anti-competitive practices in healthcare, including junk health insurance plans.

Video Saved From X

reSee.it Video Transcript AI Summary
I've identified wasteful spending in Medicare, specifically with generic Cialis, or Tadalafil. In 2022, Medicare spent $237 million on this drug, averaging $481 per prescription across 492,000 prescriptions. However, at my pharmacy, the same prescription costs only $14 without insurance. That means it would only cost $7 million to cover the entire country at my pharmacy's pricing. The overcharge of $230 million for just this one drug is due to pharmacy benefits managers (PBMs). PBMs manage all pharmacy-related aspects for Medicare, deciding coverage, copays, government costs, and pharmacy payments. They've essentially decided on a 3000% markup. It's time to fire the PBMs and bring prices back to reality. To check the markups on your prescriptions, visit forestparkpharmacy.com and use our price checker.

Video Saved From X

reSee.it Video Transcript AI Summary
Politicians have long promised to address the discrepancy between drug prices in the U.S. and Europe. This issue was central to Bernie Sanders' presidential campaigns. However, these promises were never fulfilled because Congress is heavily influenced by the pharmaceutical industry. There is at least one pharmaceutical lobbyist for every member of Congress, the Senate, and the Supreme Court.

Video Saved From X

reSee.it Video Transcript AI Summary
As a presidential candidate, the speaker plans to set drug prices based on fair market value, charging American consumers the average global price for drugs. For example, insulin prices would be impacted. If companies don't cooperate, the speaker intends to address drugs developed with federal funding. For any drug that benefited from taxpayer-funded research and development, and where companies fail to comply with pricing rules, the speaker will seize their patent. The speaker asserts this action is permissible and expresses the determination to execute it.

Video Saved From X

reSee.it Video Transcript AI Summary
Former President claims to have taken on big pharma with tough policies, but accuses President Biden of canceling them. He signed an executive order to ensure the US government pays the same price for pharmaceuticals as other countries. However, Biden rescinded this order, allegedly betraying patients and seniors. The US has been paying high prices for drugs while other countries negotiate lower prices. The former President promises to end this by signing an executive order that will only pay the best price offered to foreign nations. This will supposedly force big pharma to raise prices for other countries and reduce prices for American patients, resulting in significant savings.

Video Saved From X

reSee.it Video Transcript AI Summary
Americans pay significantly more for prescription drugs than other countries, sometimes up to 10 times more. Pharmaceutical companies generate two-thirds of their profits in the U.S., effectively making Americans subsidize healthcare in other countries. The administration is introducing a "most favored nation" pricing model, ensuring the U.S. pays the lowest price available globally for drugs. For example, a breast cancer drug costing over $16,000 in the U.S. is a fraction of that price in Australia and Sweden. Similarly, an asthma drug costs almost $500 in the U.S. but less than $40 in the UK. The plan involves directing investigations into foreign nations that block drug products unless they accept low prices, and the U.S. will defend drug companies from unfair pricing demands. The administration aims to cut out middlemen and facilitate direct drug sales at the most favored nation price. If companies don't comply, the U.S. will use its trade powers and open the market to safe, legal drug imports.

Video Saved From X

reSee.it Video Transcript AI Summary
Trump recently announced plans to break up pharmacy benefit managers (PBMs), which are often misunderstood. PBMs were created in the 1970s to help lower prescription drug costs but have since been acquired by major insurance companies, turning them into profit centers. Instead of negotiating lower prices, PBMs negotiate higher costs to receive kickbacks from drug manufacturers. For example, 30% of the cost of drugs like Ozempic goes to PBMs as kickbacks. UnitedHealthcare generated $373 billion in revenue last year, with 60% from its PBM. While insurance companies may not have as high profit margins as big pharma, they use various methods to obscure their profits. Overall, health insurance companies generate significantly more revenue than pharmaceutical companies, highlighting the hidden influence of PBMs in the healthcare system.

The Megyn Kelly Show

Trump Takes On Big Pharma with Drugs Exec Order, and Michelle Obama's Bitterness, with Walter Kirn
Guests: Walter Kirn
reSee.it Podcast Summary
Megyn Kelly opens the show by discussing significant recent developments involving President Trump, including a groundbreaking executive order on prescription drug prices and a temporary pause on tariffs with China. She highlights the economic implications of these moves, noting that experts believe the trade war with China was unsustainable for the U.S. economy. Kelly emphasizes that both Trump and Bernie Sanders share a common goal of allowing the government to negotiate drug prices, a topic that has historically faced resistance from big pharma. Kelly explains that Trump's new executive order aims to negotiate prices for all drugs, not just those under Medicare, and could potentially save Americans up to 80% on their prescriptions. She contrasts this with previous attempts by Trump and Biden, noting that the pharmaceutical industry has historically resisted such negotiations. Walter Kirn joins the discussion, agreeing that the drug pricing issue transcends party lines and is a matter of public interest. The conversation shifts to the implications of Trump's executive order, with Kirn suggesting that it could unite unlikely political allies against the powerful pharmaceutical lobby. They discuss the historical context of drug pricing in the U.S. compared to other countries, where Americans often pay significantly more for the same medications. Kelly and Kirn express skepticism about how Democrats will respond to Trump's initiative, given their past support for similar measures. The discussion then moves to Trump's recent dealings with China, where both countries have agreed to reduce tariffs temporarily while negotiating a more comprehensive trade agreement. Kelly cites market reactions and expert opinions indicating that this pause was necessary to prevent economic downturns, particularly for small businesses reliant on Chinese imports. Later, Kelly touches on a controversial incident involving the Democratic mayor of Newark and members of Congress confronting ICE officials, which escalated into a physical altercation. She criticizes the lawmakers for their aggressive behavior and suggests that such confrontations are becoming a tactic for Democrats to illustrate social issues. The show concludes with a critique of Michelle Obama’s recent comments about marriage and her public persona, with Kelly arguing that Obama’s narrative reflects a broader cultural trend of victimhood and dissatisfaction. The hosts express concern over the implications of such narratives on societal expectations and personal accountability.

This Past Weekend

Mark Cuban | This Past Weekend w/ Theo Von #533
Guests: Mark Cuban
reSee.it Podcast Summary
Audionet began in 1995 as "internet broadcasting," later becoming Broadcast.com and going public in 1998 as the biggest IPO in the history of the stock market at the time. Mark Cuban explains he started in a second bedroom, bought a PC, connected with a local radio station, and offered "Dallas sports or news from anywhere in the world" at audionet.com, which exploded and later became the leading platform before the dot-com crash. We were the first to stream basketball, football, baseball, you name it, and we were "the biggest by far." We went public, sold to Yahoo, and Yahoo "messed it up," a thread Cuban notes by recounting other Yahoo acquisitions like GeoCities and Tumblr. He mentions Yahoo’s missteps and what happened with Yahoo Finance and the overall strategy, while Theo riffs about his own Yahoo experience. Cuban recalls a tangential Diddy connection: in 2003 he redesigned a Mavericks uniform via email; he never met Diddy beyond that; he heard stories about parties but says, "I never hung out or did, and not," and regards the Diddy era as part of wealth’s temptations. He speaks about wealth creating paranoia at scale, noting that the level of wealth requires covering "every base" and that sometimes people become paranoid about privacy; he says, "I don’t like to live paranoid," preferring to enjoy money while staying grounded. He reflects on how wealth shifts priorities to family; his kids are now 15, 18 and 21, and he wants to be available as opposed to chasing the next party that used to define his younger years. Beyond business, Cuban discusses his nontraditional path: he never had a mentor, always learned by reading manuals and trying things, then applying what works. He built a personal-media empire, starting a podcast from his kitchen table and turning it into a studio; a pivotal moment came when a pizza executive in Santa Monica proposed advertising for $500 a month, convincing him to invest in a studio, helping him grow. He also recounts backing Relativity Space after a cold email, a venture that’s grown into a multi‑billion dollar company; he credits accessibility and willingness to help strangers as a recurring theme: sometimes just "making yourself available opens a lot of doors." In healthcare, Cuban launches CostPlus Drugs in 2022 to address price transparency and affordability. He explains, "costplusdrugs.com … show you our cost, our actual cost that we actually pay for it and then we mark it up 15% and then there’s $5 shipping," with further savings on many drugs, like droxidopa, which dropped from $10,000+ to $64. He emphasizes that transparency can save billions if Medicare bought at cost, and notes fiduciary issues with insurance-company contracts and the need for public price lists to empower patients. CostPlus Wellness and pricing transparency proposals tie into campaigns and policy discussions; he believes the healthcare disruption is the easiest industry to disrupt since the price lists open the market. He shares selling the Dallas Mavericks to focus on family, with a 27% stake retained; the decision was about time and strategy, not just money. Mustang, Texas, is a privately owned town he bought as a potential future project, and he keeps his kids’ birthdays aligned with family time. He opines on Elon Musk, Twitter, and the political climate, arguing that Kamala Harris represents a center-focused approach, while Trump runs a different “gangster” strategy. He believes a presidential candidate should detail policies and execution; he acknowledges the role of lobbying and the byzantine nature of politics, and he emphasizes the importance of leadership and building teams. He ends with practical advice for young people: find something you can be really good at, stay curious, be adaptable, and remember that selling—when you believe in what you sell—can become a lifelong asset. He also notes that AI will be a major future driver and that privacy, family, and time are the true riches of wealth. He also notes that AI will be a major future driver and that privacy, family, and time are the true riches of wealth.

Breaking Points

Pharma Stocks SOAR After Trump FAKE PRICE CRACKDOWN
reSee.it Podcast Summary
Trump announced an executive order aimed at reducing prescription drug prices by 30 to 80%, but the reality is more complex. He plans to investigate foreign nations that pressure drug companies into low pricing, while defending U.S. drug prices. Critics argue this approach doesn't address the core issue of high American drug costs, as pharmaceutical stocks rose following the announcement. The government has a tool called "march-in rights" to lower prices, but it has never been used effectively. The Biden administration made some reforms, yet Trump's actions suggest he lacks genuine interest in lowering drug prices.
View Full Interactive Feed